Drug Profile

Detalimogene voraplasmid - enGene Therapeutics

Alternative Names: Bladder cancer gene therapy - enGene Therapeutics; DDX^® intravesicle gene therapy - enGene Therapeutics; Detalimogene; EG-70

Latest Information Update: 22 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator enGene
Developer enGene Therapeutics
Class Antineoplastics; Gene therapies; Immunotherapies
Mechanism of Action Gene transference; Interleukin 12 replacements; RIGI protein expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

15 Jun 2026 enGene plans to conduct pre BLA meeting with the US FDA in 2H 2026
15 Jun 2026 Efficacy and adverse events data from the phase I/II LENGEND trial in Bladder cancer released by enGene
07 May 2026 Updated interim efficacy and adverse events data from the phase I/II LENGEND trial in Bladder cancer released by enGene

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com